Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.29 (market cap $8.04B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.95. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals.
| BIO | SJNK | |
|---|---|---|
Market Cap | $8.04B | — |
Sector | Health | Sector/Thematic |
52-Week High | $339.75 | $25.63 |
52-Week Low | $241.71 | $24.75 |
Enterprise Value | $7.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
SJNK trades at $24.88, down slightly by 0.12% over the past day. Technical indicators are predominantly bearish, with moving averages signaling a downtrend and oscillators neutral. The ETF continues its regular dividend payments, with recent distributions of $0.14 and $0.15 per share. Recent news highlights mixed sentiment, with some analysts cautioning on high-yield bonds while institutional positions see increases.
The outlook for SJNK is clouded by bearish technicals and cautious analyst sentiment, though steady dividends provide income support. Key risks include interest rate sensitivity and credit spread volatility in the high-yield bond market. Investors should weigh the income generation against potential capital depreciation in a rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
